A Phase 1 Study in Healthy Volunteers to Evaluate UDP glucuronosyl transferase (UGT) and Cytochrome (CYP) P450 - Mediated Drug-Drug Interactions Between GS-9688 and Probe Drugs
Phase 1
Completed
- Conditions
- Hepatitis B
- Registration Number
- ACTRN12617000700336
- Lead Sponsor
- Gilead Sciences, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the UGT and CYP450 enzyme interactions of GS-9688 in healthy volunteers?
How does GS-9688 compare to other antiviral agents in managing Hepatitis B drug metabolism?
What biomarkers indicate potential drug-drug interactions with GS-9688 in Phase 1 trials?
What adverse events are associated with GS-9688 and how are they managed in clinical settings?
Are there combination therapies involving GS-9688 for Hepatitis B under investigation by Gilead Sciences?